Back to top

Image: Bigstock

Patterson Cos. (PDCO) Up 0.3% Since Last Earnings Report: Can It Continue?

Read MoreHide Full Article

It has been about a month since the last earnings report for Patterson Cos. . Shares have added about 0.3% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Patterson Cos. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, estimates revision have trended downward during the past month.

VGM Scores

Currently, Patterson Cos. has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Patterson Cos. has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Performance of an Industry Player

Patterson Cos. is part of the Zacks Medical - Dental Supplies industry. Over the past month, West Pharmaceutical Services (WST - Free Report) , a stock from the same industry, has gained 1.6%. The company reported its results for the quarter ended December 2024 more than a month ago.

West Pharmaceutical reported revenues of $748.8 million in the last reported quarter, representing a year-over-year change of +2.3%. EPS of $1.82 for the same period compares with $1.83 a year ago.

West Pharmaceutical is expected to post earnings of $1.30 per share for the current quarter, representing a year-over-year change of -16.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -5.5%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for West Pharmaceutical. Also, the stock has a VGM Score of D.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


West Pharmaceutical Services, Inc. (WST) - free report >>

Published in